Literature DB >> 16434499

Rare occurrence of the JAK2 V617F mutation in AML subtypes M5, M6, and M7.

Stefan Fröhling, Daniel B Lipka, Sabine Kayser, Claudia Scholl, Richard F Schlenk, Hartmut Döhner, D Gary Gilliland, Ross L Levine, Konstanze Döhner.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16434499      PMCID： PMC1895918          DOI： 10.1182/blood-2005-09-3644

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  9 in total

1.  A unifying mutation in chronic myeloproliferative disorders.

Authors:  John M Goldman
Journal:  N Engl J Med       Date:  2005-04-28       Impact factor: 91.245

Review 2.  On the molecular origins of the chronic myeloproliferative disorders: it all makes sense.

Authors:  Kenneth Kaushansky
Journal:  Blood       Date:  2005-04-07       Impact factor: 22.113

3.  The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia.

Authors:  Ross L Levine; Marc Loriaux; Brian J P Huntly; Mignon L Loh; Miroslav Beran; Eric Stoffregen; Roland Berger; Jennifer J Clark; Stephanie G Willis; Kim T Nguyen; Nikki J Flores; Elihu Estey; Norbert Gattermann; Scott Armstrong; A Thomas Look; James D Griffin; Olivier A Bernard; Michael C Heinrich; D Gary Gilliland; Brian Druker; Michael W N Deininger
Journal:  Blood       Date:  2005-08-04       Impact factor: 22.113

4.  Constitutive activation of the JAK2/STAT5 signal transduction pathway correlates with growth factor independence of megakaryocytic leukemic cell lines.

Authors:  R Y Liu; C Fan; R Garcia; R Jove; K S Zuckerman
Journal:  Blood       Date:  1999-04-01       Impact factor: 22.113

5.  Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.

Authors:  Ross L Levine; Martha Wadleigh; Jan Cools; Benjamin L Ebert; Gerlinde Wernig; Brian J P Huntly; Titus J Boggon; Iwona Wlodarska; Jennifer J Clark; Sandra Moore; Jennifer Adelsperger; Sumin Koo; Jeffrey C Lee; Stacey Gabriel; Thomas Mercher; Alan D'Andrea; Stefan Fröhling; Konstanze Döhner; Peter Marynen; Peter Vandenberghe; Ruben A Mesa; Ayalew Tefferi; James D Griffin; Michael J Eck; William R Sellers; Matthew Meyerson; Todd R Golub; Stephanie J Lee; D Gary Gilliland
Journal:  Cancer Cell       Date:  2005-04       Impact factor: 31.743

6.  Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders.

Authors:  Amy V Jones; Sebastian Kreil; Katerina Zoi; Katherine Waghorn; Claire Curtis; Lingyan Zhang; Joannah Score; Rachel Seear; Andrew J Chase; Francis H Grand; Helen White; Christine Zoi; Dimitris Loukopoulos; Evangelos Terpos; Elisavet-Christine Vervessou; Beate Schultheis; Michael Emig; Thomas Ernst; Eva Lengfelder; Rüdiger Hehlmann; Andreas Hochhaus; David Oscier; Richard T Silver; Andreas Reiter; Nicholas C P Cross
Journal:  Blood       Date:  2005-05-26       Impact factor: 22.113

7.  HEL cells: a new human erythroleukemia cell line with spontaneous and induced globin expression.

Authors:  P Martin; T Papayannopoulou
Journal:  Science       Date:  1982-06-11       Impact factor: 47.728

8.  The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both "atypical" myeloproliferative disorders and myelodysplastic syndromes.

Authors:  David P Steensma; Gordon W Dewald; Terra L Lasho; Heather L Powell; Rebecca F McClure; Ross L Levine; D Gary Gilliland; Ayalew Tefferi
Journal:  Blood       Date:  2005-04-28       Impact factor: 22.113

9.  JAK2 mutation 1849G>T is rare in acute leukemias but can be found in CMML, Philadelphia chromosome-negative CML, and megakaryocytic leukemia.

Authors:  Jaroslav Jelinek; Yasuhiro Oki; Vazganush Gharibyan; Carlos Bueso-Ramos; Josef T Prchal; Srdan Verstovsek; Miloslav Beran; Elihu Estey; Hagop M Kantarjian; Jean-Pierre J Issa
Journal:  Blood       Date:  2005-07-21       Impact factor: 22.113
  9 in total
  15 in total

1.  RNAi screening of the tyrosine kinome identifies therapeutic targets in acute myeloid leukemia.

Authors:  Jeffrey W Tyner; Denise K Walters; Stephanie G Willis; Mary Luttropp; Jason Oost; Marc Loriaux; Heidi Erickson; Amie S Corbin; Thomas O'Hare; Michael C Heinrich; Michael W Deininger; Brian J Druker
Journal:  Blood       Date:  2007-11-19       Impact factor: 22.113

2.  Absence of JAK2 V617F mutation in thalassemia intermedia patients.

Authors:  Ali Taher; Dina Shammaa; Ali Bazarbachi; Doha Itani; Ghazi Zaatari; Layal Greige; Zaher K Otrock; Rami A R Mahfouz
Journal:  Mol Biol Rep       Date:  2008-09-10       Impact factor: 2.316

3.  The prognostic impact of germline 46/1 haplotype of Janus kinase 2 in cytogenetically normal acute myeloid leukemia.

Authors:  Sarolta Nahajevszky; Hajnalka Andrikovics; Arpad Batai; Emma Adam; Andras Bors; Judit Csomor; Laszlo Gopcsa; Magdalena Koszarska; Andras Kozma; Nora Lovas; Sandor Lueff; Zoltan Matrai; Nora Meggyesi; Janos Sinko; Andrea Sipos; Andrea Varkonyi; Sandor Fekete; Attila Tordai; Tamas Masszi
Journal:  Haematologica       Date:  2011-07-26       Impact factor: 9.941

Review 4.  JAK2 V617F in myeloid disorders: molecular diagnostic techniques and their clinical utility: a paper from the 2005 William Beaumont Hospital Symposium on Molecular Pathology.

Authors:  David P Steensma
Journal:  J Mol Diagn       Date:  2006-09       Impact factor: 5.568

5.  New treatments and strategies in acute myeloid leukemia.

Authors:  Farhad Ravandi
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2011-04-30

6.  Refractory anemia with ringed sideroblasts associated with marked thrombocytosis (RARS-T), another myeloproliferative condition characterized by JAK2 V617F mutation.

Authors:  Hadrian Szpurka; Ramon Tiu; Gurunathan Murugesan; Samer Aboudola; Eric D Hsi; Karl S Theil; Mikkael A Sekeres; Jaroslaw P Maciejewski
Journal:  Blood       Date:  2006-06-01       Impact factor: 22.113

7.  Genomic and functional analysis of leukemic transformation of myeloproliferative neoplasms.

Authors:  Raajit Rampal; Jihae Ahn; Omar Abdel-Wahab; Michelle Nahas; Kai Wang; Doron Lipson; Geoff A Otto; Roman Yelensky; Todd Hricik; Anna Sophia McKenney; Gabriela Chiosis; Young Rock Chung; Suveg Pandey; Marcel R M van den Brink; Scott A Armstrong; Ahmet Dogan; Andrew Intlekofer; Taghi Manshouri; Christopher Y Park; Srdan Verstovsek; Franck Rapaport; Philip J Stephens; Vincent A Miller; Ross L Levine
Journal:  Proc Natl Acad Sci U S A       Date:  2014-12-02       Impact factor: 11.205

8.  Mutations of e3 ubiquitin ligase cbl family members constitute a novel common pathogenic lesion in myeloid malignancies.

Authors:  Hideki Makishima; Heather Cazzolli; Hadrian Szpurka; Andrew Dunbar; Ramon Tiu; Jungwon Huh; Hideki Muramatsu; Christine O'Keefe; Eric Hsi; Ronald L Paquette; Seiji Kojima; Alan F List; Mikkael A Sekeres; Michael A McDevitt; Jaroslaw P Maciejewski
Journal:  J Clin Oncol       Date:  2009-11-09       Impact factor: 44.544

9.  Comparison of mutated ABL1 and JAK2 as oncogenes and drug targets in myeloproliferative disorders.

Authors:  C Walz; N C P Cross; R A Van Etten; A Reiter
Journal:  Leukemia       Date:  2008-06-05       Impact factor: 11.528

10.  Cell cycle control in acute myeloid leukemia.

Authors:  Dominik Schnerch; Jasmin Yalcintepe; Andrea Schmidts; Heiko Becker; Marie Follo; Monika Engelhardt; Ralph Wäsch
Journal:  Am J Cancer Res       Date:  2012-08-20       Impact factor: 6.166
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.